To examine whether enhanced anti-tumor effects occur independently of p53 when AZD1152 and TTFields are combined, we initially used the p53 wild-type, long-term-established glioma cell line U87-MG and its stable p53-deficient counterpart U87-MGshp53. The gene discussed is TP53; the disease is glioma.